PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)

Bibliographic Details
Main Authors:	G. Tsykunova, P. A. Holme, H. Thi Thyuet Tran, T. H. A. Tvedt, L. Munthe, M. Michel, H. Frederiksen, J. Bussel, D. Kuter, W. Ghanima
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000852076.33574.89

Similar Items

2313
by: Nikhil Satchidanand, et al.
Published: (2017-09-01)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
by: Elena Vaneeva, et al.
Published: (2023-08-01)

2313 Characterization of the host pericyte role in glioblastoma angiogenesis
by: Frank Attenello, et al.
Published: (2018-06-01)

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
by: A. Åkesson, et al.
Published: (2022-06-01)

S293: RISK OF FRACTURES IN ADULT PATIENTS WITH PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA: A DANISH NATIONWIDE COHORT STUDY
by: N. Mannering, et al.
Published: (2022-06-01)

Rilzabrutinib placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
by: David J. Kuter, et al.
Published: (2023-10-01)

Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)
by: Sif Gudbrandsdottir, et al.
Published: (2017-07-01)

Chess clock using synthesized risc microcontroller based on Atmel AT90S2313 /
by: 453746 Mohd. Rafzan Zainol, et al.
Published: (2005)

A TMEL AT90S2313 8 bit microcontroller design using FPGA /
by: 226317 Gan, Ai Chee, et al.
Published: (2005)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
by: David Kuter, et al.
Published: (2023-08-01)

The spleen in immune thrombocytopenia
by: Julia T. Geyer, et al.
Published: (2018-06-01)

Advances in the management of alloimmune thrombocytopenia.
by: Murphy, M, et al.
Published: (2007)

Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study
by: Alexander Åkesson, et al.
Published: (2023-12-01)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Sagar Lonial, et al.
Published: (2023-08-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Sebastian Grosicki, et al.
Published: (2023-08-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists
by: Lamya Garabet, et al.
Published: (2020-04-01)

Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?
by: James Bussel, et al.
Published: (2019-08-01)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
by: Ekaterina Ilicheva, et al.
Published: (2023-08-01)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
by: Aimaz Afrough, et al.
Published: (2023-10-01)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
by: Hanny Al-Samkari, et al.
Published: (2019-04-01)

Thrombocytopenia in Virus Infections
by: Matthijs Raadsen, et al.
Published: (2021-02-01)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
by: Vivek Bhat, et al.
Published: (2023-08-01)

(2313) Proposal to conserve the name Momordica lanata (Citrullus lanatus) (watermelon, Cucurbitaceae), with a conserved type, against Citrullus battich
by: Renner, S, et al.
Published: (2014)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
by: F. Kapsouli, et al.
Published: (2022-06-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment
by: Waleed Ghanima, et al.
Published: (2019-02-01)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
by: R. Fonseca, et al.
Published: (2022-06-01)

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
by: Monica Carpenedo, et al.
Published: (2023-08-01)

PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
by: D. De Novellis, et al.
Published: (2022-06-01)

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists
by: Lamya Garabet, et al.
Published: (2020-02-01)

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
by: Abraham Z. Cheloff, et al.
Published: (2020-07-01)

Daratumumab: A drug with transfusion dilemma
by: Amit Kumar Biswas, et al.
Published: (2023-01-01)

Daratumumab-induced transient myopic shift
by: Maria A. Mavrommatis, et al.
Published: (2019-03-01)

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
by: H. Elsabah, et al.
Published: (2022-06-01)

Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia
by: Lamya Garabet, et al.
Published: (2019-02-01)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. V. Mateos, et al.
Published: (2022-06-01)